Note: Abingdon Health has further expanded its facilities since this press release. Click here to learn more.
Following a successful 2019, Abingdon Health is expanding its York-based facility, giving the company the space and capabilities necessary to continue to drive forward rapid diagnostic testing innovation and growth.
Abingdon Health, which develops and manufactures lateral flow rapid diagnostic tests, saw its revenue increase by 90% in 2019, due to several new contract wins and the development of its AppDx Smartphone reader software, which was the catalyst for its recent expansion. The expansion will see the company grow their footprint by 42 per cent, including new quality-control and research and development laboratories, increased assembly space and client meeting rooms.
From its National Agri-Food Innovation Campus location in York (now know as York Biotech Campus), Abingdon Health will also be able to accommodate the increasing demand for customer on-site visits and expand the volume of product batches which can be manufactured at one time.
2019 also saw Abingdon Health’s employee levels expand by 20% with this increase in personnel set to grow in 2020 and beyond.
Chris Yates, Chief Executive at Abingdon Health commented:
“We are very excited about the next phase of our business growth and this expansion will give us the ability to invest in our team and continue to meet the increasing demand for our assay and reader services.”
The recent growth of Abingdon Health is testament to the increasing demand for rapid testing, especially in the area of mHealth. Contact Abingdon Health for more information about lateral flow rapid diagnostics and their services.
